Meeting
2021 ASCO Annual Meeting
Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.
Authors
Changgong Zhang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
Changgong Zhang , Sheng Yang , Jianhua Chen , Huijuan Wu , Jun Wang , Yingping Li , Liying Gao , Zhongyao Jia , Yan Sun , Jun Zhao , Xin Lin Mu , Chunmei Bai , Rui Wang , Kailiang Wu , Qiang Liu , Xiaoping Jin , Xiaowen Tan , Yuankai Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04203719
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8568)
DOI
10.1200/JCO.2021.39.15_suppl.8568
Abstract #
8568
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin
Poster
2022 ASCO Annual Meeting
Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.
First Author: Changgong Zhang
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Yonggui Hong